

**2023 ASCO Cancer Communications Committee Disclosures**

All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution

Name	Employment	Leadership	Stock and Other Ownership Interests	Honoraria	Consulting or Advisory Role	Speakers' Bureau	Research Funding	Patents, Royalties, Other Intellectual Property	Expert Testimony	Travel, Accommodations, Expenses	Other Relationship	(OPTIONAL) Uncompensated Relationships	(OPTIONAL) Open Payments Link
Charu Aggarwal					Astra Zeneca BeiGene Blueprint Genetics Boehringer Ingelheim Celgene Daiichi Sankyo/Astra Zeneca Eisai Genentech Janssen Lilly Merck Pfizer Regeneron/ Sanofi Shionogi Turning Point Therapeutics	AstraZeneca (I)  Roche/Genentech (I)	AstraZeneca/MedImmune (Inst) Genentech/Roche (Inst) Incyte (Inst) MacroGenics (Inst) Merck Sharp & Dohme (Inst)						
Lauren A. Byers				Clinical Care Options UpToDate	Abbvie Amgen Arrowhead Pharmaceuticals AstraZeneca BeiGene Chugal Pharmaceutical Co. Daiichi Sankyo Genetech Inc. Jazz Pharmaceuticals Merck Sharp & Dohme Corp. Puma Biotechnology		Amgen (Inst) AstraZeneca (Inst) Jazz Pharmaceuticals (Inst)						
Elizabeth A. Comen	Survivornet		Survivornet.com	ClearView Healthcare Partners Decision Resources Gerson Lehrman Group Grey Global Group Kantar Health Kantar Health Navigant Consulting Pfizer Pfizer Pfizer	Bristol-Myers Squibb Genentech HERON Novartis Novartis Novartis Pfizer Pfizer Pfizer		Hoffmann La Roche		Novartis Pfizer Pfizer				
Curtiland Deville					AstraZeneca Blue Earth Diagnostics								
Robert Dreicer					Astellas Pharma AstraZeneca AVEO Bayer Exelixis Gilead Sciences Hengrui Pharmaceutical Hinova Pharmaceuticals Janssen Oncology Merck Pfizer Sanofi genzyme Tavanta		Bristol-Myers Squibb (Inst) Exelixis (Inst) Seattle Genetics (Inst)						

Cathy Eng					Amgen (I)  California Institute for Regenerative Medicine (CIRM) (I)  California Institute for Regenerative Medicine (CIRM) (I)  Elevar (Inst) Elevation Oncology General Electric GlaxoSmithKline Gritstone (Inst) IgM Biosciences (I)  Janssen Oncology Merck (Inst) Merck Serono natera Pfizer Pfizer (Inst) Seagen Taiho Oncology (I)		Astellas Pharma (Inst) Gritstone Bio (Inst) hutchinson (Inst) Janssen Oncology (Inst) Merck (Inst) Pfizer (Inst)						
Mark T. Fleming	Virginia Oncology Associates	US Oncology			Dendreon Janssen Oncology	Genentech Janssen Oncology			Genentech Medivation/Astellas				
Julie R. Galow					Genentech Roche								
Glenn J. Hanna	Dana-Farber Cancer Institute			Bristol-Myers Squibb Kura Oncology	Bicara Boxer Capital Bristol-Myers Squibb Exicure General Catalyst KSQ Therapeutics Kura Oncology Merck Naveris Prelude Therapeutics Rain Therapeutics Remix Therapeutics Sanofi/Genzyme SIRPant		Actuate Therapeutics (Inst) ASCO Conquer Cancer Foundation Bicara Therapeutics (Inst) Bristol-Myers Squibb (Inst) Elevar (Inst) Exicure (Inst) Gateway for Cancer Research GlaxoSmithKline (Inst) Kartos Therapeutics (Inst) Kite/Gilead (Inst) Kite/Gilead (Inst) NantKwest, (Inst) Regeneron (Inst) Sanofi Genzyme (Inst) Secura Bio (Inst) V Foundation		Aaronson Rappaport Feinstein & Deutsch LLP Ahmuty, Demers, & McManus, Esqs Wilson Elser Moskowitz Edelman & Dicker, LLP				
Melissa M. Hudson					Oncology Research Information Exchange Network Princess Máxima Center								
Pamela L. Kunz					Amgen Crinetics Pharmaceuticals Genentech/Roche HUTCHMED Ipsen Isotope Technologies Munich SE (ITM) Natera Novartis (Advanced Accelerator Applications)		Novartis (Advanced Accelerator Applications) (Inst)						
Michael C. Lowe					Bristol-Myers Squibb/Pfizer		Bristol-Myers Squibb (Inst) Castle Biosciences (Inst) Delcath Systems (Inst) Regeneron (Inst) Skyline Diagnostics (Inst) Vaccinex (Inst)						

Erica L. Mayer					AstraZeneca Diacc Gilead Sciences Lilly Novartis								
Bradley A. McGregor					Astellas Pharma Bristol-Myers Squibb Calithera Biosciences Eisai EMD Serono Exelixis Genentech/Roche Merck Cga Pfizer Seattle Genetics/Astellas		Bristol-Myers Squibb (Inst) Calithera Biosciences (Inst) Exelixis (Inst) Pfizer/EMD Serono (Inst) Seattle Genetics/Astellas (Inst)						
Kathleen N. Moore		GOG Partners NRG Ovarian Committee Chair (Inst)		Great Debates and Updates Physician Education Resource Prime Oncology Research To Practice	AADi alkermes (Inst) AstraZeneca Blueprint pharmaceuticals (Inst) Caris Life Sciences Clovis Oncology Eisai Genentech/Roche GSK/Tesaro (Inst) Hengrui Pharmaceutical Imab (Inst) Immunogen InxMed (Inst) Iovance Biotherapeutics Merck Mereo BioPharma Mersana (Inst) Myriad Genetics Novartis Novartis/Pfizer Onconova Therapeutics OncXerna Therapeutics VBL Therapeutics Verastem/Pharmacyclics		Agenus (Inst) Amgen (Inst) artios (Inst) AstraZeneca (Inst) Bolt Biotherapeutics (Inst) Bristol-Myers Squibb (Inst) Clovis Oncology (Inst) cyteir (Inst) Daiichi Sankyo/Lilly (Inst) Genentech (Inst) Immunocore (Inst) Immunogen (Inst) Lilly (Inst) Lilly Foundation (Inst) Merck (Inst) Novartis Pharmaceuticals UK Ltd. (Inst) Novogen (Inst) PTC Therapeutics (Inst) Regeneron (Inst) Takeda (Inst) Tesaro (Inst) Verastem (Inst)	#Up to Date		astra zeneca GSK	GOG Partners (Inst)		
Rita Nanda					AstraZeneca BeyondSpring Pharmaceuticals Cardinal Health Fujifilm GE Healthcare Gilead Sciences Infinity Pharmaceuticals ITeos Therapeutics Merck OBI Pharma OncoSec Sanofi Seattle Genetics		Arvinas (Inst) AstraZeneca (Inst) Celgene (Inst) Corcept Therapeutics (Inst) Genentech/Roche (Inst) Immunomedics (Inst) Merck (Inst) OBI Pharma (Inst) Odonate Therapeutics (Inst) OncoSec (Inst) Pfizer (Inst) Relay Therapeutics (Inst) Seattle Genetics (Inst) Sun Pharma (Inst) Taiho Oncology (Inst)				G1 Therapeutics		
Oreofe O. Odejide Olatoyosi Odenike					Abbvie Blueprint Medicines BMS Bristol-Myers Squibb/Celgene (Inst) Celgene CTI Biopharma Impact Biomedicines Kymera Novartis SERVIER Taiho Threadwell therapeutics		Abbvie (Inst) Agiost (Inst) Aprea AB (Inst) Astex Pharmaceuticals (Inst) AstraZeneca (Inst) Bristol-Myers Squibb (Inst) Celgene (Inst) CTI BioPharma Corp (Inst) Daiichi Sankyo (Inst) Incyte (Inst) Janssen Oncology (Inst) Kartos (Inst) Loxo (Inst) Novartis (Inst) NS Pharma (Inst) Oncotherapy (Inst)						

Ann H. Partridge								#I receive small royalty payments for co-authoring the breast cancer survivorship section of UpToDate					
Corey W. Speers					Exact Sciences			#Compositions and Methods for the Analysis of Radiosensitivity, UM-33550/US-1, Coinventor, Submitted on 09/2013  #Methods and Genomic Classifiers for Prognosis of Breast Cancer and Predicting Benefit from Adjuvant Radiotherapy, Application No. 61/205,279, Co-inventor, Submitted on					
Jennifer F. Tseng					Aegerion (I) Amgen (I) AstraZeneca (I) Bristol-Myers Squibb (I) Cubist (I) Curadel Surgical Innovations Daiichi Sankyo/Lilly (I) GlaxoSmithKline (I) Intarcia Therapeutics (I) Merck (I) MyoKardia (I) PanTher Therapeutics Pfizer (I) Quest Diagnostics (I) Sanofi (I) Vertex (I) Zeus (I)								